move right direct
go take time multi-year journey
maintain equal weight rate believ manag make
right move simpli take time correct view decad
mismanag preced current manag team backdrop
challeng market environ character persist price pressur
zbh pe move higher turnaround hope believ stock alreadi
price success share trade slight discount
end-market healthier growth tangibl sustain moreov
believ zimmer biomet sale ep growth like continu lag
compani manag continu reinvest potenti sale upsid
target level acceler top-lin look bring
potenti near-term dilut shift portfolio rais weight averag
view street margin ep assumpt may bit high mayb
much beyondw see zimmer biomet
modest growth compani turn around gross margin
like y/i oper margin could flattish mayb modest /-
gross margin could still fx hedg gain around
year look neutral y/i howev could becom
headwind fx hedg gain moder go away becom loss price
pressur sinc like like back
reduct focu manag like take
time flow due long inventori turn cours acceler
sale growth could help eas concern margin front
model pt chang updat forecast reflect result
pt rais reflect pe prior ep given sale momentum
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year see prospect
signific sale margin expans
limit near-term
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
zimmer biomet zb sale ep came street/our estim
constant currenc basi sale estim manag
comment first half headwind bill day off-set
estim provid tailwind also benefit buy ahead
japanes consumpt tax zb reiter full-year guidanc net/net view
result favor believ zb still long road restor compani higher
level sustain sale growth margin pressur like persist continu
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
constant currenc sale growth ahead wamgr help
sell day benefit buy ahead japanes consumpt tax growth
driven continu perform apac emea well
stabil america
knee sale ahead street/our expect rosa
acceler sequenti contribut quarter manag note
still earli half overal growth came new product base
 sale street/our estim manag
highlight suppli stabil new product launch traction special sale
channel drive result categori
hip sale street/our expect manag
note two driver potenti above-market growth longer term avenir complet
system anterior approach well eventu applic rosa hip
despit beat zb didnt rais full-year guidanc cite number benefit
quarter contribut above-wamgr growth nonetheless zb posit
growth line wamgr albeit like low end
headwind like emea rebat year ago quarter
sale report basi constant currenc
basi constant currenc growth vari knee hip
spine cmf dental
gross margin y/i driven number item includ
med-tech tax refund fx hedg ad
sg sale y/i dollar basi driven
new product launch sale forc expans
 sale y/i
oper margin y/i driven gm expans
adjust tax rate flat y/i
adjust ep street estim estim
manag expect grow line wamgr
manag reiter prior guidanc though fx expect closer high end rang sale
expect flat report basi oper margin expect adjust tax rate
expect manag expect adjust ep
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
